IFNG and melanoma: In the context of melanoma, MDMs trigger glucocorticoid signaling that activates an array of checkpoint receptors including PD-1, Tim-3, LAG-3, and IL-10, and reduces levels of pro-inflammatory cytokines such as TNF-α, IL-2, and IFN-γ.